A Phase 1/2 interventional study of Acalabrutinib in Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma and Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia, sponsored by AstraZeneca. Active, not recruiting at 23 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell — 5 open to participants now, 20 under way, 1 of them phase 3. acalabrutinib · Lymphoma, Mantle-Cell.
Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, this one is the 6th largest by enrollment, is one of 5 that started in 2020, is one of 3 in phase 1/2, reaches primary completion later than 3 of the 19 other live ones, and was the 7th registered.
1,220 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →5 of the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Emory University · Sites in United States
Ages 18+
Austin I Kim · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 2 · Phase 4 1
First in 2015; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 49 across the 26 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 26 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
15 studies in Lymphoma, Mantle-Cell by AstraZeneca: 3 open now, 8 under way, 1 of them phase 3. Of 6 finished, 3 (50%) have results posted.
Among the 15 studies in Lymphoma, Mantle-Cell by AstraZeneca, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 1/2, and was the 8th registered.
AstraZeneca’s Lymphoma, Mantle-Cell studies by the year they started, since 2005.
7 of the studies testing acalabrutinib in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02972840Phase 3Acerta Pharma BVA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | 2027-02-15 |
| NCT04115631ECOG-ACRIN Cancer Research GroupA Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | 2026-12-31 |
| NCT04484012City of Hope Medical CenterModified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | 2027-02-23 |
| NCT05495464M.D. Anderson Cancer CenterA Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | 2027-03-31 |
| NCT04189757M.D. Anderson Cancer CenterAcalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, from their registry updates:
Among AstraZeneca’s 15 in Lymphoma, Mantle-Cell:
This tab as a report to print or save as PDF → With an account.
This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies. The study is divided into 2 parts: Phase 1 portion and Phase 2 portion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.
Drug: Acalabrutinib
Acalabrutinib 100 mg orally twice daily
Phase I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. A SAE is an AE occurring during any study phase, that fulfils 1 or more of the following criteria: death, life-threatening, in-participant hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital abnormality or birth defect, and an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AEs leading to discontinuation of acalabrutinib were those with action taken was 'Drug Permanently Discontinued' for acalabrutinib.
Time frame: From the first dose administration up to 30 days following the date of last dose of study treatment, approximately 25 months.
Phase I: Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
Blood samples were collected to determine the AUCinf of acalabrutinib and ACP-5862 in plasma. The AUCinf was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Phase I: Area Under the Plasma Concentration-Time Curve From Zero to 12 Hours (AUC0-12) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
Blood samples were collected to determine the AUC0-12 of acalabrutinib and ACP-5862 in plasma. The AUC0-12 was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1
Phase I: Area Under the Plasma Concentration-Time Curve From Zero to the Time of the Last Quantifiable Concentration (AUClast) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
Blood samples were collected to determine the AUClast of acalabrutinib and ACP-5862 in plasma. The AUClast was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Phase I: Maximum Observed Plasma Drug Concentration (Cmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib
Blood samples were collected to determine the Cmax of acalabrutinib and ACP-5862 in plasma. The Cmax was determined using non-compartmental method.
Time frame: Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Time to Reach Maximum Observed Concentration (Tmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib
Blood samples were collected to determine the tmax of acalabrutinib and ACP-5862 in plasma. The tmax was determined using non-compartmental method.
Time frame: Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Apparent Total Body Clearance of Drug (CL/F) of Acalabrutinib Post Single and Multiple Dose of Acalabrutinib
Urine samples were collected to determine the CL/F of acalabrutinib. The CL/F was determined using non-compartmental method.
Time frame: Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Apparent Volume of Distribution (Vz/F) of Acalabrutinib Post Single Dose of Acalabrutinib
Blood samples were collected to determine the Vz/F of acalabrutinib in plasma. The Vz/F was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Phase I: Terminal Elimination Rate Constant (λz) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
Blood samples were collected to determine the λz of acalabrutinib and ACP-5862 in plasma. The λz was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Phase I: Terminal Phase Half-Life (t1/2λz) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
Blood samples were collected to determine the t1/2λz of acalabrutinib and ACP-5862 in plasma. The t1/2λz was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Phase I: Metabolite/Parent Drug Cmax Ratio (MRCmax) of Acalabrutinib and ACP-5862 Post Single and Multiple Dose of Acalabrutinib
Blood samples were collected to determine the MRCmax of acalabrutinib and ACP-5862 in plasma. The MRCmax was determined using non-compartmental method.
Time frame: Single dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8 and 12 hours postdose on Cycle 0 Day 1; Multiple dose: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Metabolite/Parent Drug AUC Ratio (MRAUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib
Blood samples were collected to determine the MRAUCinf of acalabrutinib in plasma. The MRAUCinf was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 0 Day 1
Phase I: Area Under the Plasma Concentration-Time Curve Across the Dosing Interval (AUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
Blood samples were collected to determine the AUCτ of acalabrutinib and ACP-5862 in plasma. The AUCτ was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Minimum Observed Plasma Drug Concentration (Cmin) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
Blood samples were collected to determine the Cmin of acalabrutinib and ACP-5862 in plasma. The Cmin was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Metabolite/Parent Drug AUCτ Ratio (MRAUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
Blood samples were collected to determine the MRAUCτ of acalabrutinib and ACP-5862 in plasma. The MRAUCτ was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Temporal Change Parameter (TCP) in Systemic Exposure of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
Blood samples were collected to determine the TCP of acalabrutinib and ACP-5862 in plasma. The TCP in systemic exposure was calculated as AUCτ (steady state)/AUCinf (first dose). The TCP was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Accumulation Ratio of AUCτ (Rac AUC) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
Blood samples were collected to determine the Rac AUC of acalabrutinib and ACP-5862 in plasma. The Rac AUC was calculated as AUCτ (steady state)/AUCτ (first dose). The Rac AUC was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase I: Accumulation Ratio of Cmax (Rac Cmax) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib
Blood samples were collected to determine the Rac Cmax of acalabrutinib and ACP-5862 in plasma. The Rac Cmax was calculated as Cmax (steady state)/Cmax (first dose). The Rac Cmax was determined using non-compartmental method.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 and 48 hours postdose on Cycle 1 Day 8
Phase II: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR)
The ORR \[based on International workshop on chronic lymphocytic leukemia (iwCLL) 2018 criteria as assessed by the BICR\] was defined as the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR), and partial response (PR). The ORR and the corresponding 95% 2-sided confidence interval (CI) of ORR were presented based on Clopper-Pearson exact method.
Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Phase I: Best Overall Response (BOR) Assessed by Investigator in Participants With R/R CLL
The BOR is best response a participant has had following first dose date but prior to starting any subsequent anticancer therapy up to and including progression or last evaluable assessment in absence of progression. The CR: No lymph nodes \>=1.5 centimeters. The CRi: Participants who fulfill all criteria for CR but have a persistent anemia, thrombocytopenia or neutropenia apparently unrelated to CLL but related to drug toxicity. The nPR: Participants who were in a complete remission but bone marrow nodules can be identified histologically. The PR: Disease \>=50% from baseline. Partial response with lymphocytosis (PRL): Presence of lymphocytosis plus \>=50% reduction in lymphadenopathy and/or in spleen or liver enlargement plus 1 of PR criteria for platelets or hemoglobin must be met. Stable disease (SD): Change of -49% to +49% in lymph nodes. PD: Increase \>=50% from baseline or from response.
Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days thereafter or more frequently at the investigator's discretion, approximately 25 months
Phase I: Best Overall Response Assessed by Investigator in Participants With R/R MCL
The BOR is best response a participant has had following first dose date but prior to starting any subsequent anticancer therapy up to and including progression or last evaluable assessment in absence of progression. CR: No lymph nodes \>=1.5 centimeters. PR: Disease \>=50% from baseline. SD: Change of -49% to +49% in lymph nodes. PD: Increase \>=50% from baseline or from response.
Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days thereafter or more frequently at the investigator's discretion, approximately 25 months
Phase II: ORR Assessed by Investigator
The ORR (based on iwCLL 2018 criteria as assessed by the Investigator) was defined as the percentage of participants who achieved a CR, CRi, nPR, and PR. The ORR and the corresponding 95% 2-sided CI of ORR were presented based on Clopper-Pearson exact method.
Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Phase II: Duration of Response (DoR) Assessed by BICR and Investigator
The DoR (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval from the first documentation of objective response to the earlier of the first documentation of objective PD or death from any cause. The DoR was calculated using Kaplan-Meier technique.
Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Phase II: Progression-Free Survival (PFS) Assessed by BICR and Investigator
The PFS (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval from the start of acalabrutinib therapy to the earlier of the first documentation of objective PD or death from any cause. The PFS was calculated using Kaplan-Meier technique.
Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Phase II: Time to Response (TTR) Assessed by BICR and Investigator
The TTR (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval between the date of first dose and the date of initial documentation of a response.
Time frame: Response evaluations performed at the end of Cycles 2, 4 and 6; and then every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Phase II CLL Only: Time to Next Treatment (TTNT)
The TTNT was defined as the interval from the start of acalabrutinib therapy to institution of non-protocol specified anticancer treatment for CLL or death due to any cause, whichever came first. The TTNT was calculated using Kaplan-Meier technique.
Time frame: Response evaluations performed every 12 weeks +/- 7 days through Cycle 25, and then every 24 weeks +/- 7 days thereafter. Assessed until 18 December 2023.
Phase II CLL Only: Percentage of Participants With Minimal Residual Disease (MRD) Negativity
The MRD negative rate was defined as the percentage of participants with MRD-negativity (\<1 CLL cell per 10000 leukocytes) measured in the peripheral blood by flow cytometry.
Time frame: At screening (-28 days) and end of treatment visit. Assessed until 18 December 2023.
Phase II: Percentage of Participants With Overall Survival (OS) at Month 6
The OS was defined as the interval from the start of acalabrutinib therapy to death from any cause. The OS was calculated using Kaplan-Meier technique.
Time frame: From the first dose administration up to Month 6
Phase II: Plasma Concentration of Acalabrutinib
Blood samples were collected to determine the plasma concentration of acalabrutinib.
Time frame: At 1, 2 and 4 hours post-dose on Day 8, 15 and 22 of Cycle 1
This Phase I/II open-label study was conducted in participants with relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R chronic lymphocytic leukemia (CLL) or other B-cell malignancies at 20 study centers in China. The Phase II CLL results are reported for analysis with assessment until data cut-off (DCO) date of 18 December 2023. PD= Progressive disease.
| Milestone | Phase I | Phase II MCL | Phase II CLL |
|---|---|---|---|
| Started | 12 | 33 | 60 |
| Participants from phase i who entered phase ii mcl | 0 | 1 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 12 | 33 | 60 |
| Withdrew: Death | 0 | 7 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 |
| Withdrew: Meet the point of final analysis for this cohort | 8 | 23 | 0 |
| Withdrew: Progressive disease | 3 | 0 | 0 |
| Withdrew: Lung infection | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 58 |
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. A SAE is an AE occurring during any study phase, that fulfils 1 or more of the following criteria: death, life-threatening, in-participant hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital abnormality or birth defect, and an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AEs leading to discontinuation of acalabrutinib were those with action taken was 'Drug Permanently Discontinued' for acalabrutinib.
| Participants | Phase I |
|---|---|
| Any AE | 12 |
| Any SAE | 2 |
| Any AE leading to discontinuation of Acalabrutinib | 1 |
| Any AE with outcome death | 0 |
Blood samples were collected to determine the AUCinf of acalabrutinib and ACP-5862 in plasma. The AUCinf was determined using non-compartmental method.
| hour*nanogram per milliliter (h*ng/mL) | Phase I |
|---|---|
| Acalabrutinib | 1351 ± 47.99 |
| ACP-5862 | 2421 ± 29.46 |
Blood samples were collected to determine the AUC0-12 of acalabrutinib and ACP-5862 in plasma. The AUC0-12 was determined using non-compartmental method.
| h*ng/mL | Phase I |
|---|---|
| Acalabrutinib | 1310 ± 50.39 |
| ACP-5862 | 2008 ± 37.76 |
Blood samples were collected to determine the AUClast of acalabrutinib and ACP-5862 in plasma. The AUClast was determined using non-compartmental method.
| h*ng/mL | Phase I |
|---|---|
| Acalabrutinib | 1343 ± 48.40 |
| ACP-5862 | 2270 ± 32.82 |
Blood samples were collected to determine the Cmax of acalabrutinib and ACP-5862 in plasma. The Cmax was determined using non-compartmental method.
| ng/mL | Phase I |
|---|---|
| Post single dose: Acalabrutinib | 967.6 ± 59.52 |
| Post single dose: ACP-5862 | 628.1 ± 46.38 |
| Post multiple dose: Acalabrutinib | 958.2 ± 60.99 |
| Post multiple dose: ACP-5862 | 710.0 ± 38.08 |
Blood samples were collected to determine the tmax of acalabrutinib and ACP-5862 in plasma. The tmax was determined using non-compartmental method.
| hour | Phase I |
|---|---|
| Post single dose: Acalabrutinib | 0.50 (0.48 to 1.02) |
| Post single dose: ACP-5862 | 0.88 (0.73 to 2.00) |
| Post multiple dose: Acalabrutinib | 0.50 (0.27 to 2.03) |
| Post multiple dose: ACP-5862 | 1.00 (0.73 to 3.95) |
Urine samples were collected to determine the CL/F of acalabrutinib. The CL/F was determined using non-compartmental method.
| liter per hour | Phase I |
|---|---|
| Post single dose | 74.01 ± 36.77 |
| Post multiple dose | 72.81 ± 45.25 |
Blood samples were collected to determine the Vz/F of acalabrutinib in plasma. The Vz/F was determined using non-compartmental method.
| liter | Phase I |
|---|---|
| Phase I: Apparent Volume of Distribution (Vz/F) of Acalabrutinib Post Single Dose of Acalabrutinib | 171.3 ± 105.5 |
Blood samples were collected to determine the λz of acalabrutinib and ACP-5862 in plasma. The λz was determined using non-compartmental method.
| 1/hour | Phase I |
|---|---|
| Acalabrutinib | 0.43212 ± 51.085 |
| ACP-5862 | 0.096102 ± 19.036 |
Blood samples were collected to determine the t1/2λz of acalabrutinib and ACP-5862 in plasma. The t1/2λz was determined using non-compartmental method.
| hour | Phase I |
|---|---|
| Acalabrutinib | 1.604 ± 76.21 |
| ACP-5862 | 7.213 ± 28.03 |
Blood samples were collected to determine the MRCmax of acalabrutinib and ACP-5862 in plasma. The MRCmax was determined using non-compartmental method.
| ratio | Phase I |
|---|---|
| Post single dose | 0.6276 ± 37.87 |
| Post multiple dose | 0.7662 ± 43.08 |
Blood samples were collected to determine the MRAUCinf of acalabrutinib in plasma. The MRAUCinf was determined using non-compartmental method.
| ratio | Phase I |
|---|---|
| Phase I: Metabolite/Parent Drug AUC Ratio (MRAUCinf) of Acalabrutinib and ACP-5862 Post Single Dose of Acalabrutinib | 1.732 ± 31.55 |
Blood samples were collected to determine the AUCτ of acalabrutinib and ACP-5862 in plasma. The AUCτ was determined using non-compartmental method.
| h*ng/mL | Phase I |
|---|---|
| Acalabrutinib | 1373 ± 43.62 |
| ACP-5862 | 2707 ± 28.61 |
Blood samples were collected to determine the Cmin of acalabrutinib and ACP-5862 in plasma. The Cmin was determined using non-compartmental method.
| ng/mL | Phase I |
|---|---|
| Acalabrutinib | 2.443 ± 148.0 |
| ACP-5862 | 37.52 ± 37.58 |
Blood samples were collected to determine the MRAUCτ of acalabrutinib and ACP-5862 in plasma. The MRAUCτ was determined using non-compartmental method.
| ratio | Phase I |
|---|---|
| Phase I: Metabolite/Parent Drug AUCτ Ratio (MRAUCτ) of Acalabrutinib and ACP-5862 Post Multiple Dose of Acalabrutinib | 1.906 ± 33.26 |
Blood samples were collected to determine the TCP of acalabrutinib and ACP-5862 in plasma. The TCP in systemic exposure was calculated as AUCτ (steady state)/AUCinf (first dose). The TCP was determined using non-compartmental method.
| ratio | Phase I |
|---|---|
| Acalabrutinib | 1.017 ± 37.57 |
| ACP-5862 | 1.118 ± 17.15 |
Blood samples were collected to determine the Rac AUC of acalabrutinib and ACP-5862 in plasma. The Rac AUC was calculated as AUCτ (steady state)/AUCτ (first dose). The Rac AUC was determined using non-compartmental method.
| ratio | Phase I |
|---|---|
| Acalabrutinib | 1.048 ± 37.97 |
| ACP-5862 | 1.348 ± 41.64 |
Blood samples were collected to determine the Rac Cmax of acalabrutinib and ACP-5862 in plasma. The Rac Cmax was calculated as Cmax (steady state)/Cmax (first dose). The Rac Cmax was determined using non-compartmental method.
| ratio | Phase I |
|---|---|
| Acalabrutinib | 0.8218 ± 59.99 |
| ACP-5862 | 1.130 ± 70.23 |
The ORR \[based on International workshop on chronic lymphocytic leukemia (iwCLL) 2018 criteria as assessed by the BICR\] was defined as the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi), nodular partial response (nPR), and partial response (PR). The ORR and the corresponding 95% 2-sided confidence interval (CI) of ORR were presented based on Clopper-Pearson exact method.
| percentage of participants | Phase II MCL | Phase II CLL |
|---|---|---|
| Phase II: Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) | 82.4 (65.5 to 93.2) | 86.7 (75.4 to 94.1) |
The BOR is best response a participant has had following first dose date but prior to starting any subsequent anticancer therapy up to and including progression or last evaluable assessment in absence of progression. The CR: No lymph nodes \>=1.5 centimeters. The CRi: Participants who fulfill all criteria for CR but have a persistent anemia, thrombocytopenia or neutropenia apparently unrelated to CLL but related to drug toxicity. The nPR: Participants who were in a complete remission but bone marrow nodules can be identified histologically. The PR: Disease \>=50% from baseline. Partial response with lymphocytosis (PRL): Presence of lymphocytosis plus \>=50% reduction in lymphadenopathy and/or in spleen or liver enlargement plus 1 of PR criteria for platelets or hemoglobin must be met. Stable disease (SD): Change of -49% to +49% in lymph nodes. PD: Increase \>=50% from baseline or from response.
| Participants | Phase I |
|---|---|
| CR | 0 |
| CRi | 0 |
| nPR | 0 |
| PR | 4 |
| PRL | 0 |
| SD | 0 |
| PD | 0 |
| Not evaluable | 0 |
The BOR is best response a participant has had following first dose date but prior to starting any subsequent anticancer therapy up to and including progression or last evaluable assessment in absence of progression. CR: No lymph nodes \>=1.5 centimeters. PR: Disease \>=50% from baseline. SD: Change of -49% to +49% in lymph nodes. PD: Increase \>=50% from baseline or from response.
| Participants | Phase I |
|---|---|
| CR | 1 |
| PR | 4 |
| SD | 0 |
| PD | 3 |
| Not evaluable | 0 |
The ORR (based on iwCLL 2018 criteria as assessed by the Investigator) was defined as the percentage of participants who achieved a CR, CRi, nPR, and PR. The ORR and the corresponding 95% 2-sided CI of ORR were presented based on Clopper-Pearson exact method.
| percentage of participants | Phase II MCL | Phase II CLL |
|---|---|---|
| Phase II: ORR Assessed by Investigator | 73.5 (55.6 to 87.1) | 85.0 (73.4 to 92.9) |
The DoR (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval from the first documentation of objective response to the earlier of the first documentation of objective PD or death from any cause. The DoR was calculated using Kaplan-Meier technique.
| months | Phase II MCL | Phase II CLL |
|---|---|---|
| BICR Assessment | NA (6.4 to NA) | NA (25.00 to NA) |
| Investigator Assessment | NA (11.2 to NA) | NA (26.38 to NA) |
The PFS (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval from the start of acalabrutinib therapy to the earlier of the first documentation of objective PD or death from any cause. The PFS was calculated using Kaplan-Meier technique.
| months | Phase II MCL | Phase II CLL |
|---|---|---|
| BICR Assessment | NA (5.55 to NA) | NA (28.32 to NA) |
| Investigator Assessment | NA (5.55 to NA) | NA (30.62 to NA) |
The TTR (based on iwCLL 2018 criteria as assessed by the BICR and Investigator) was defined as the interval between the date of first dose and the date of initial documentation of a response.
| months | Phase II MCL | Phase II CLL |
|---|---|---|
| BICR Assessment | 1.8 (1.6 to 3.7) | 5.06 (2.7 to 16.6) |
| Investigator Assessment | 1.9 (1.6 to 3.7) | 5.52 (2.7 to 22.2) |
The TTNT was defined as the interval from the start of acalabrutinib therapy to institution of non-protocol specified anticancer treatment for CLL or death due to any cause, whichever came first. The TTNT was calculated using Kaplan-Meier technique.
| months | Phase II CLL |
|---|---|
| Phase II CLL Only: Time to Next Treatment (TTNT) | NA (NA to NA) |
The MRD negative rate was defined as the percentage of participants with MRD-negativity (\<1 CLL cell per 10000 leukocytes) measured in the peripheral blood by flow cytometry.
| percentage of participants | Phase II CLL |
|---|---|
| Phase II CLL Only: Percentage of Participants With Minimal Residual Disease (MRD) Negativity | 0 |
The OS was defined as the interval from the start of acalabrutinib therapy to death from any cause. The OS was calculated using Kaplan-Meier technique.
| percentage of participants | Phase II MCL | Phase II CLL |
|---|---|---|
| Phase II: Percentage of Participants With Overall Survival (OS) at Month 6 | NA (NA to NA) | 96.7 (87.3 to 99.2) |
Blood samples were collected to determine the plasma concentration of acalabrutinib.
| nanogram per milliliter | Phase II MCL | Phase II CLL |
|---|---|---|
| Cycle 1 Day 8: 1 hour | 157.3 ± 103.6 | 238.7 ± 288.2 |
| Cycle 1 Day 8: 2 hour | 155.0 ± 70.33 | 187.2 ± 111.4 |
| Cycle 1 Day 8: 4 hour | 77.06 ± 94.19 | 58.73 ± 115.4 |
| Cycle 1 Day 15: 1 hour | 160.3 ± 90.00 | 206.6 ± 354.3 |
| Cycle 1 Day 15: 2 hour | 178.9 ± 70.41 | 195.7 ± 152.2 |
| Cycle 1 Day 15: 4 hour | 61.31 ± 75.60 | 49.96 ± 162.4 |
| Cycle 1 Day 22: 1 hour | 196.3 ± 93.17 | — |
| Cycle 1 Day 22: 2 hour | 121.3 ± 87.67 | — |
| Cycle 1 Day 22: 4 hour | 100.8 ± 162.3 | — |
Collected over Phase I and Phase II MCL: Treatment-emergent adverse events and all-cause mortality were reported from the first dose administration up to 30 days following the date of last dose of study treatment, approximately 25 months. Phase II CLL: Treatment-emergent adverse events and all-cause mortality were reported from the first dose administration up to 30 days following the date of last dose of study treatment, approximately 41 months. Assessed until DCO 18 December 2023.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I | 0/12 (0%) | 2/12 (16.7%) | 12/12 (100%) |
| Phase II MCL | 7/34 (20.6%) | 6/34 (17.6%) | 28/34 (82.4%) |
| Phase II CLL | 2/60 (3.3%) | 21/60 (35%) | 56/60 (93.3%) |
| Event | Phase I | Phase II MCL | Phase II CLL |
|---|---|---|---|
| Covid-19Infections and infestations | 0/12 | 0/34 | 6/60 |
| Pneumonia fungalInfections and infestations | 1/12 | 0/34 | 0/60 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/12 | 0/34 | 1/60 |
| Covid-19 pneumoniaInfections and infestations | 0/12 | 0/34 | 5/60 |
| PneumoniaInfections and infestations | 0/12 | 2/34 | 4/60 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/12 | 1/34 | 0/60 |
| Aplastic anaemiaBlood and lymphatic system disorders | 0/12 | 1/34 | 0/60 |
| Inguinal herniaGastrointestinal disorders | 0/12 | 1/34 | 0/60 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/12 | 1/34 | 0/60 |
| Gastrointestinal infectionInfections and infestations | 0/12 | 1/34 | 0/60 |
| Event | Phase I | Phase II MCL | Phase II CLL |
|---|---|---|---|
| Neutrophil count decreasedInvestigations | 4/12 | 7/34 | 28/60 |
| White blood cell count decreasedInvestigations | 5/12 | 3/34 | 3/60 |
| Platelet count decreasedInvestigations | 4/12 | 14/34 | 24/60 |
| AnaemiaBlood and lymphatic system disorders | 4/12 | 8/34 | 14/60 |
| HyperuricaemiaMetabolism and nutrition disorders | 4/12 | 5/34 | 8/60 |
| PurpuraSkin and subcutaneous tissue disorders | 4/12 | 0/34 | 1/60 |
| Covid-19Infections and infestations | 0/12 | 0/34 | 16/60 |
| Upper respiratory tract infectionInfections and infestations | 3/12 | 8/34 | 11/60 |
| HeadacheNervous system disorders | 3/12 | 7/34 | 10/60 |
| HaematuriaRenal and urinary disorders | 3/12 | 3/34 | 4/60 |
The Safety analysis set included all participants who received at least 1 dose of acalabrutinib. A total of 105 unique participants were enrolled in the study.
| Age, Categorical(Participants) | Phase I | Phase II MCL | Phase II CLL | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 22 | 37 | 66 |
| >=65 years | 5 | 11 | 23 | 39 |
| Sex: Female, Male(Participants) | Phase I | Phase II MCL | Phase II CLL | Total |
|---|---|---|---|---|
| Female | 7 | 4 | 19 | 30 |
| Male | 5 | 29 | 41 | 75 |
| Race/Ethnicity, Customized(Participants) | Phase I | Phase II MCL | Phase II CLL | Total |
|---|---|---|---|---|
| Asian | 12 | 33 | 60 | 105 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2020 to primary completion in Dec 2022, 31 months.
Results were first posted in Mar 2025, 2 years 2 months after primary completion.
Of 77 phase 1/2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 114. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib